

# **Certificate of Analysis for NR-20534**

### Burkholderia multivorans, Strain CGD2

#### Catalog No. NR-20534

### **Product Description:**

Burkholderia multivorans (B. multivorans), strain CGD2 was isolated prior to 2007 from a human respiratory sample from a patient with chronic granulomatous disease in Maryland, USA.

Lot: 70026743<sup>1</sup> Manufacturing Date: 27JUN2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Report results	Gram-negative rods
Colony morphology <sup>2</sup>	Report results	Circular, convex, entire, smooth, mucoid and white (Figure 1)
Motility (wet mount)	Report results	Motile
Biochemical characterization	•	
VITEK® 2 Compact (GN card)	B. multivorans (≥ 89.9%)	B. multivorans (99%)
VITEK® MS (MALDI-TOF)	B. multivorans	B. multivorans (99.9%)
Antibiotic Susceptibility Profile <sup>3</sup> VITEK® (AST-GN81 Card)		, ,
Ampicillin	Report results	Resistant (≥ 32 μg/mL)
Amoxicillin/Clavulanic Acid	Report results	Resistant (≥ 32 μg/mL)
Piperacillin/Tazobactam	Report results	Resistant (≥ 128 µg/mL)
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Report results	Sensitive (≤ 1 μg/mL)
Ceftriaxone	Report results	Sensitive (≤ 1 μg/mL)
Meropenem	Report results	Sensitive (1 µg/mL)
Amikacin	Report results	Resistant (≥ 64 µg/mL)
Gentamicin	Report results	Resistant (≥ 16 μg/mL)
Tobramycin	Report results	Resistant (≥ 16 μg/mL)
Ciprofloxacin	Report results	Resistant (2 μg/mL)
Levofloxacin	Report results	Intermediate (4 µg/mL)
Tetracycline	Report results	Resistant (≥ 16 μg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 μg/mL)
Trimethoprim/sulfamethoxazole	Report results	Sensitive (≤ 20 μg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene	≥ 99% sequence identity to	99.9% sequence identity to
(~ 1470 base pairs)	B. multivorans, strain CGD2 (GenBank: ACFC01000015.1)	B. multivorans, strain CGD2 (GenBank: ACFC01000015.1) <sup>4</sup>
Purity (post-freeze) <sup>5</sup>	Consistent with expected colony morphology	Consistent with expected colony morphology
Viability (post-freeze) <sup>2</sup>	Growth	Growth

<sup>&</sup>lt;sup>1</sup>NR-20534 was produced by inoculation of the deposited material into Tryptic Soy broth and grown 1 day at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub>. Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles and grown 1 day at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> to produce this lot.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

<sup>&</sup>lt;sup>2</sup>1 day at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> on Tryptic Soy agar with 5% defibrinated sheep blood

<sup>&</sup>lt;sup>3</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)


<sup>&</sup>lt;sup>4</sup>Also consistent with other Burkholderia species

<sup>&</sup>lt;sup>5</sup>Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with 5% CO<sub>2</sub> on Tryptic Soy agar with 5% defibrinated sheep blood.



# **Certificate of Analysis for NR-20534**

Figure 1: Colony Morphology



/Heather Couch/ Heather Couch

19 AUG 2019

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected by ATCC® to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

 $ATCC^{\otimes}$  is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898